Participated · Series A · Dec 2025

Ember LifeSciences develops reusable, modular cold-chain shipping platforms, including the flagship Ember Cube and the newly commercially available Ember Cube 2, which features real-time monitoring and cloud-based tracking. The Ember Cube 2 has received design recognition such as a Red Dot “Best of the Best,” and the company’s products have been cited by TIME and Fast Company. Ember’s customer base includes major pharmaceutical distributors and pharmacies such as CVS Health, Cardinal Health, Chartwell and USADA. The company originated as an offshoot of Ember Technologies, the maker of a temperature-control mug that has exceeded half a billion dollars in total sales. Ember says it will use recent strategic investments to scale its logistics platform rapidly and expand its global footprint.

Participated · Series A · Jul 2022

RxLive provides an AI-powered medication management software, telepharmacy services, and a population health pharmacy analytics platform serving a national customer base of healthcare providers. Founded in 2018 and based in St. Petersburg, Florida, the company combines analytics and telepharmacy to support population health pharmacy needs. RxLive raised $5M in a Series A and has now raised $8M in total to date. The company intends to use the Series A proceeds to expand its engineering, analytics, and sales and marketing teams. It also plans to invest in continuous improvement of its AI and the functionality of its medication management platform. The funding is positioned to support product development and broader deployment to its national customer base.

Participated · Equity · Jan 2022

Medically Home’s core product is a platform and ecosystem that unlocks patients’ homes as safe alternative sites for delivering hospital-level and lower-acuity care. The model combines centralized clinical oversight in medical command centers with field clinicians (nurses, paramedics, technicians) and relies on national partners for medications, equipment, technology, and supportive services. Medically Home has treated over 7,000 patients to date and reports rapidly expanding utilization across health systems. The company says the model increases health system capacity and resiliency while meeting patient preferences for home-based care. Recent strategic investment activity is intended to strengthen logistics and clinical capacity to scale the model nationwide and to grow a next‑generation clinical workforce. Medically Home partners with hospitals to provide hospital-level care in patients’ homes. The company helps hospitals parse logistics for in-home services such as X-rays, diagnostic lab testing, and infusion services while clinicians manage patients virtually. Mayo Clinic and Kaiser Permanente are investing $100 million in the startup. Both health systems have been partnering with Medically Home to roll out hospital-at-home services over the last year. The investment aligns with growing reimbursement flexibilities and CMS programs that have encouraged providers to adopt hospital-at-home models. The company and the model face challenges related to variable patient home environments, including space and internet connectivity affecting digital care delivery. Medically Home Group provides a virtual hospital that transforms patients' homes into temporary hospital units, enabling advanced medical care at bedside. Its offering allows healthcare providers to deliver a clinically-validated program intended to improve patient experience while reducing costs. The company's solutions include clinical intellectual property, a technology platform, a Mission Control Telemedicine Command Center and acute rapid response clinical services. Medically Home's platform is designed to allow medical providers to safely shift advanced medical care from hospitals to patients' homes. Led by CEO Richard Rakowski and based in Boston, MA, the company raised financing to support growth. The company intends to use the funds to scale its growth efforts.

Led · Series C · Oct 2020

Vineti provides a commercial, configurable cloud-based Personalized Therapy Management (PTM) platform that integrates logistics, manufacturing, and clinical data for personalized and high-value advanced therapies. The platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic cell therapies, and can be harnessed for drug products requiring companion diagnostics or REMS programs. Vineti serves patients, healthcare providers, and researchers in hundreds of leading medical centers and manufacturing centers worldwide on behalf of biopharmaceutical partners. Co-founded by GE and the Mayo Clinic and led by CEO Amy DuRoss, Vineti is now a fully independent company. The company has offices in San Francisco, Bethesda, Maryland, and Yerevan, Armenia. The new financing will support further expansion of the PTM platform. Vineti provides a cloud-based platform of record that integrates logistics, manufacturing and clinical data to align and orchestrate the cell and gene therapy process. Its configurable software automates and simplifies complex workflows behind individualized therapies and enables integrations with other parts of the therapy ecosystem. The platform is designed to improve product performance as personalized therapies move into mainstream medicine. Led by CEO and co-founder Amy DuRoss, the company targets pharmaceutical partners developing individualized treatments. Vineti plans to use the new funding to extend its technology platform and expand into Europe and the Asia‑Pacific region. Vineti provides a commercial cloud-based platform that integrates logistics, manufacturing and clinical data to support individualized cell therapies. The platform is designed to improve product performance, promote safety and regulatory compliance, and enable faster, broader patient access. Vineti aims to accelerate life-saving treatment delivery for individualized therapies. The company was co-founded by GE and the Mayo Clinic and is led by CEO Amy DuRoss, chief strategy officer Heidi Hagen, CTO Razmik Abnous and chief science officer Malek Faham. It closed a $13.75M Series A and intends to use the proceeds to grow its team. Backers on the round included GE Ventures, Mayo Clinic Ventures, DFJ and LifeForce Capital.

Participated · Series B · Jan 2016

Enlace Health, formerly Aver, delivers an end-to-end, extensible solution designed to bridge technical silos and enable payers, providers, and patients to operate within a Triple‑Aim-focused healthcare model. The Enlace platform operates in the background without disrupting existing systems and supports retrospective, prospective, and complete‑risk programs. The company emphasizes a continuous “Design, Analyze, Implement, Administer” process and leverages deep client partnerships to drive product innovation. Enlace positions its offering as the infrastructure needed for value‑based care and to solve delivery and economic challenges in healthcare. The firm announced a $58‑plus million investment to accelerate scale and deployment of the Enlace Health brand. The rebrand and capital are intended to support organic growth, strategic partnerships, and further product and service expansion as market acceptance grows. Aver offers a tech-enabled platform to design, analyze, implement, and operationalize episode-based bundled payment and value-based care contracts for payers and large health systems. The product emphasizes administrative simplicity, high configuration flexibility, automated analytics and reporting, real-time patient-journey monitoring, and a HITRUST-certified enterprise infrastructure. Aver reports customers have seen more than 20% savings in medical spend and over 40% reduction in complications in bundled programs. The company plans to scale operations and expand platform capabilities to better support payer customers in executing bundled payment and value-based programs. Aver positions itself as a leading provider of analytics, network services, and administrative capabilities to ease the transition from fee-for-service to value-based contracts. Aver offers the Aver Cloud suite and a patented data management platform that builds and administers bundled payments around episodes of care, with analytics and reports to measure performance in fee-for-value models. Its tools support commercial, Medicare, and Medicaid plans as well as health care providers, enabling creation, management, insight, and payment processing for value-based programs. The company says it has seen very strong growth driven by accelerated adoption of bundled payment solutions among leading health systems and payers. Aver cites strong 2015 results and anticipated growth in 2016 as factors behind its recent financing. The funding is intended to help scale operations, expand platform capabilities, and grow market share as the healthcare sector shifts toward value-based reimbursement. The company emphasizes its role in helping customers adapt to payment models tied to cost and quality.